Vimarsana
Biggest News Aggregation in the World

Page 3 - Hematologic Disorders News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hematologic Disorders. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hematologic Disorders Today - Breaking & Trending Today

FDA Committee Unanimous on Two Gene Therapies - Vimarsana News

FDA Committee Unanimous on Two Gene Therapies

An FDA advisory committee gave a unanimous thumbs up to two new gene therapies, one for beta-thalassemia and the other for a rare but fatal neurologic disorder.

'It's an Amazing Time to Be a Hemophilia Provider' - Vimarsana News

'It's an Amazing Time to Be a Hemophilia Provider'

New drugs such as emicizumab (Hemlibra) are transforming the lives of patients with hemophilia A, and more are on their way. "It's an amazing time to be a hemophilia provider," says Alice D. Ma, MD.

Global Genetic Testing Markets Report 2022-2027: Pharmacogenomics Drives Further Growth, Oncology and Liquid Biopsy Enter New Era, Direct to Consumer Begins to Break Out - Vimarsana News

Global Genetic Testing Markets Report 2022-2027: Pharmacogenomics Drives Further Growth, Oncology and Liquid Biopsy Enter New Era, Direct to Consumer Begins to Break Out

/PRNewswire/ -- The "Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic impact With Executive and...

9/11 First Responders Show Mutations Linked to Blood Cancers - Vimarsana News

9/11 First Responders Show Mutations Linked to Blood Cancers

First responders who were exposed to toxic dusts and fibers in the aftermath of the World Trade Center terror attacks show increased levels of clonal hematopoiesis linked to the development of blood cancers.

NHS England Treats First Sickle Cell Patients with 'Life-Changing' Drug - Vimarsana News

NHS England Treats First Sickle Cell Patients with 'Life-Changing' Drug

Around 5000 patients are likely to benefit from the drug over the next 3 years.